Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
FDA Clears Multi-Disease AI Screening Platform for CT Imaging
HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
•AuntMinnie
AI Projected to Reshape Radiologist Workload But Not Eliminate Jobs
Stanford researchers predict AI could reduce radiologist hours by up to 49% over the next five years, though workforce size is likely to remain stable due to rising imaging demand.
•Cardiovascular Business
FDA Expands Clearance for AI-Guided Echo Exams on Existing Ultrasound Systems
FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.